Hikma Pharmaceuticals

Hikma Pharmaceuticals's reported carbon emissions

In 2025, Hikma Pharmaceuticals reported total greenhouse gas emissions of approximately 1.1 billion kg CO2e. This total includes 46,742,000 kg CO2e from Scope 1 emissions, 92,575,000 kg CO2e from Scope 2 emissions, and 827,185,000 kg CO2e from Scope 3 emissions. The company has set an ambitious target to reduce its Scope 1 and 2 greenhouse gas emissions by 25% by 2030, using a 2020 baseline. This commitment reflects a proactive approach to climate action, aiming for significant reductions in its operational footprint. Hikma has also reported a 4% decrease in its GHG emissions from direct fuel usage and electricity consumption since 2017. The company is on track to meet its near-term reduction targets, demonstrating a commitment to sustainability and environmental responsibility. Furthermore, Hikma aims to achieve net zero emissions by 2050, encompassing all scopes of emissions, which underscores its long-term dedication to combating climate change. Overall, Hikma Pharmaceuticals is actively working towards reducing its carbon emissions and enhancing its sustainability practices, aligning with industry standards and expectations for corporate climate action.